Everything below concerns MC4R. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2026-07-03. Numbers and descriptions here follow the published literature rather than marketing material.
Clinical programmes in this area have relied mainly on randomised, double-blind, placebo-controlled designs in premenopausal women. Primary endpoints usually combine a validated questionnaire covering desire domains with counts of satisfying sexual events and a separate measure of distress. Reported outcomes show statistically significant but modest average improvement over placebo, with wide individual variation. Adverse events such as nausea, flushing, and headache occur frequently and can limit tolerability. Whether short-term trial gains translate into lasting change for most users is an open question.
Evidence outside the studied population is sparse. Trials have concentrated on premenopausal women with a defined diagnosis, and data for postmenopausal women, men, and people taking interacting medications remain limited. Non-prescription use of the peptide for comparable goals is widespread but is not supported by published controlled data. Observed changes in blood pressure have drawn attention to cardiovascular monitoring during use. The literature generally frames the compound as a targeted receptor agonist rather than a general libido enhancer, and basic questions about mechanism and long-term safety are unresolved.
Bremelanotide functions as an agonist at several melanocortin receptor subtypes, with the strongest functional activity reported at the MC4 subtype. MC4 receptors sit in hypothalamic circuits that influence appetite, energy balance, and components of sexual behaviour. Rodents lacking functional MC4 receptors show altered mating behaviour, which supports a role for this pathway in desire. The precise sequence of events connecting receptor activation to reported human effects remains only partly characterised. Because the same receptor family governs pigmentation and inflammatory signalling, selectivity is a recurring theme in pharmacological discussion.
PT-141 is the research code for bremelanotide, a cyclic heptapeptide derived from alpha-melanocyte-stimulating hormone. The molecule belongs to the melanocortin receptor agonist family and shows highest affinity for the MC4 receptor subtype, with weaker activity at MC1, MC3 and MC5. Its structure retains the core His-Phe-Arg-Trp sequence that defines melanocortin recognition, while cyclization and terminal modifications improve metabolic stability relative to the parent hormone. Early work classified the compound as a centrally acting agent rather than a peripherally acting vasodilator, which shaped subsequent development priorities.
Receptor activation in hypothalamic and limbic circuits is the mechanism most often cited for the observed effects on sexual desire. Signalling through MC4R couples to Gs proteins and raises intracellular cyclic AMP, which in turn modulates dopaminergic tone in reward-related pathways. Because the peptide reaches the central nervous system after subcutaneous administration, peripheral vascular changes are regarded as secondary rather than primary. The precise neural circuits that translate receptor occupancy into behavioural change remain incompletely mapped, and published accounts describe the pathway in general terms rather than as a fully resolved sequence.
Development began with intranasal formulations investigated for erectile dysfunction, but blood pressure elevation limited that route and prompted a switch to subcutaneous delivery. Clinical testing then shifted toward hypoactive sexual desire disorder in premenopausal women, and a subcutaneous product received United States approval in 2019. Later trials examined other populations with mixed results, and questions about effect size, durability and patient selection remain open in the peer-reviewed literature. Research interest continues in parallel with the broader melanocortin field, where several synthetic analogues are studied together.
| Property | Value | Notes |
|---|---|---|
| Primary receptor target | MC4 melanocortin receptor | Other melanocortin subtypes are also activated |
| Typical route in approved use | Subcutaneous injection | Single-use format in the marketed product |
| Elimination half-life | Roughly two to three hours | Short exposure supports as-needed use |
| Common adverse events | Nausea, flushing, headache | Generally transient but can be dose limiting |
| Main studied group | Premenopausal women with low desire | Controlled data outside this group are limited |
Bremelanotide acts as an agonist at melanocortin receptors, a family of five G-protein-coupled receptors labeled MC1 through MC5. Binding studies indicate activity at several of these subtypes rather than strict selectivity for one. Signalling proceeds mainly through Gs-mediated activation of adenylyl cyclase, raising intracellular cyclic AMP. The MC4 receptor, expressed in hypothalamic and limbic circuits, is widely regarded as the subtype most relevant to sexual response. Because the molecule is not subtype-selective, effects at other melanocortin receptors are expected and are used to explain some observed side effects.
The peptide contains seven amino acids arranged in a ring, closed by a lactam bridge between a side-chain acid and an amine. This cyclic constraint holds the backbone in a defined conformation and increases resistance to enzymatic breakdown relative to linear analogs. N-terminal acetylation and a C-terminal amide further protect the molecule from exopeptidases. The result is a compound with a comparatively long circulation time for a small peptide. Structural modification of the bridge alters receptor affinity, which is one reason analogs in this family differ in their subtype preferences.
Whether the behavioral effect originates centrally, peripherally, or through both remains an active question. Animal experiments using receptor antagonists and site-specific injections point toward hypothalamic melanocortin circuits as a key locus, but translating those findings to humans is not straightforward. Blood pressure changes observed in trials suggest a vascular component that may be peripherally mediated. The relationship between receptor occupancy and reported effect has not been mapped in humans, and no validated biomarker predicts response. This gap makes it difficult to explain individual variability on pharmacological grounds alone.
Nearly 20,000 suspected armed OLF members, some of which were believed to be unarmed civilians (including children) were forcibly held in military camps in three different regions for the purpose of disarming and "re-educat[ing]" them, although very few had been released by the end of 1992. Throughout this time, the country's judiciary had failed to adequately adjudicate cases or to hold the TGE and its forces accountable for rights abuses. This was largely due to disruptions such as the looming threat of a possible suspension of all judges who were associated with the former Workers' Party of Ethiopia, the abrupt resignation of the Minister of Justice, a lack of an operating police force. These types of abuses persisted throughout the remainder of the transitional period. Freedom of the press was limited; in the first half of 1994, at least twenty journalists were fined or jailed as a result of publishing content that challenged the government, a situation exacerbated by the fact that the contemporary press laws were vague and improperly implemented. Human rights organizations including the Ethiopian Human Rights Council were denied formal registration from the government but continued to process complaints and report abuses; the government accused EHRCO of being a politically-motivated group with a hidden agenda that favored opposition groups and reported false information. Individuals suspected to have been previously associated with the OLF were treated particularly harshly once they were detained in secret detention centers across the country.
Analogous to the behavior of other chalcogens, selenium forms hydrogen selenide, H2Se. It is a strongly odiferous, toxic, and colorless gas. It is more acidic than H2S. In solution it ionizes to HSe−. The selenide dianion Se2− forms a variety of compounds, including the minerals from which selenium is obtained commercially. Illustrative selenides include mercury selenide (HgSe), lead selenide (PbSe), zinc selenide (ZnSe), and copper indium gallium diselenide (Cu(Ga,In)Se2). These materials are semiconductors. With highly electropositive metals, such as aluminium, these selenides are prone to hydrolysis, which may be described by this idealized equation:
A protease (also called a peptidase, proteinase, or proteolytic enzyme) is an enzyme that catalyzes proteolysis, breaking down proteins into smaller polypeptides or single amino acids, and spurring the formation of new protein products. They do this by cleaving the peptide bonds within proteins by hydrolysis, a reaction where water breaks bonds. Proteases are involved in numerous biological pathways, including digestion of ingested proteins, protein catabolism (breakdown of old proteins), and cell signaling. In the absence of functional accelerants, proteolysis would be very slow, taking hundreds of years. Proteases can be found in all forms of life including viruses. They have independently evolved multiple times, and different classes of protease can perform the same reaction by completely different catalytic mechanisms.
Sources: en.wikipedia.org
=== Backbone modifications === Nucleoside organothiophosphate (PS) analogs of nucleotides give oligonucleotides some beneficial properties. Key beneficial properties that PS backbones give nucleotides are diastereomer identification of each nucleotide and the ability to easily follow reactions involving the phosphorothioate nucleotides, which is useful in oligonucleotide synthesis. PS backbone modifications to oligonucleotides protects them against unwanted degradation by enzymes. Modifying the nucleotide backbone is widely used because it can be achieved with relative ease and accuracy on most nucleotides. Fluorescent modifications on 5' and 3' end of oligonucleotides was reported to evaluate the oligonucleotides structures, dynamics and interactions with respect to environment.
=== Recurring or guest === Avantika Vandanapu as Ophelia, a young advanced witch Madelaine Petsch as Kira, Ben's girlfriend Elle Chapman as Ashley, one of Kira's friends Berto Colón as Joe the Doorman Fedor Steer as Mr. Nas, an elderly gentleman being cared for by Constance and Ben John Waters as Mr. Phibes, a mysterious phlebotomist John Carroll Lynch as Twisty the Clown, a disgraced clown and a serial killer, reprising his role from Freak Show and Cult Tig Notaro as Ricochet, a clown school teacher Jamie Brewer as: Adelaide Langdon, Constance's daughter, reprising her role from Murder House Nan, a witch, reprising her role from Coven and Apocalypse Mena Suvari as Elizabeth Short, a ghost of an aspiring actress, reprising her role from Murder House and Apocalypse Paul Anthony Kelly as young Nas Mat Fraser as Paul the Illustrated Seal, a freak show member with phocomelia, reprising his role from Freak Show Orlando Jones as Papa Legba, a gatekeeper of the spirit world; Jones replaces Lance Reddick, who portrayed Papa Legba in Coven and Apocalypse Seth Gabel as Jeffrey Dahmer, a serial killer, reprising his role from Hotel Zach Villa as Richard Ramirez, a serial killer, reprising his role from 1984 Alex Consani as Morwenna Grace Dumdaw Cara Delevingne Charlie Carver
Such compounds are called cycloalkanes, and are also excluded from the above list because changing the number of rings changes the molecular formula. For example, cyclobutane and methylcyclopropane are isomers of each other (C4H8), but are not isomers of butane (C4H10). Branched alkanes are more thermodynamically stable than their linear (or less branched) isomers. For example, the highly branched 2,2,3,3-tetramethylbutane is about 1.9 kcal/mol more stable than its linear isomer, n-octane.
Sources: en.wikipedia.org
== Classification of MMC == MMC can be classified into physical MMC and chemical MMC. In the former method, the stationary phase is constructed of two or more types of packing materials. In the chemical method, just one type of packing material containing two or more functionalities is used.
== N == NAD – NADH – NADPH – natural environment – natural selection – nephron – nervous system – neural plate – neural tube – neuron – neuroscience – neurospora crassa – neurotransmitter – neurula – neutral theory of molecular evolution – niche – nitrogen cycle – non-competitive inhibition – non-cyclic electron flow – nondisjunction – N-terminus – nuclear lamina – nucleolus – nucleon – nucleoside – nucleosome – nucleotide – nutrition
== Applications == SFC has been used primarily for separation of chiral molecules, mainly those which required normal phase conditions. While the mobile phase is a fluid in the supercritical state, the stationary phase is packed inside columns similar to those used in liquid chromatography. Since the use of normal phase mode of chromatography remained less common, so did SFC; therefore it is now commonly used for selected chiral and achiral separations and purification in the pharmaceutical industry.
=== Genoa === In September 2021, 777 Partners bought 99.99% of Italian Serie A club Genoa CFC, the country's oldest club, founded in 1893. It became the sixth club in the league to have an American owner, and the transaction to buy the club from long-term owner Enrico Preziosi was estimated at €150 million. The club hired former AC Milan and Ukraine striker Andriy Shevchenko as the club manager in November, firing him in January 2022; Genoa ended the season relegated (as did another US-owned team, Venezia FC), but were immediately promoted back into the top division in May 2023. James Horncastle wrote in May 2024 that Genoa fans were not antagonistic toward 777, partly due to a history of mismanagement by Preziosi. Horncastle mentioned that Genoa had a one-point deduction for a late tax payment in their 2022–23 Serie B promotion season. On 18 December 2024, Genoa CFC announced that new majority stakeholder Dan Șucu, a Romanian businessman and owner of FC Rapid București and Mobexpert had taken over the club by paying €45m for 77% of the club. The following day, A-CAP released a statement advising that they still own the club, however, the board of Genoa CFC maintains that the sale is final.
Sources: en.wikipedia.org
The approved formulation is given by subcutaneous injection and is used on an as-needed basis rather than on a fixed daily schedule. An intranasal version was studied earlier but did not reach the same stage of development. Route of delivery strongly affects how quickly the peptide appears in circulation.
It means the product is taken shortly before anticipated activity instead of every day. This pattern reduces total exposure and shapes how safety monitoring is planned. It also means effects are expected to be temporary rather than cumulative.
Desire is assessed through validated self-report questionnaires, sometimes paired with event counts and a distress scale. These instruments capture subjective experience, so results depend on how participants interpret the questions. No laboratory marker currently substitutes for such reporting.
The code designates bremelanotide, a cyclic heptapeptide melanocortin receptor agonist. It served as an internal research identifier before the compound entered formal clinical development. The code and the generic name refer to the same molecule.